(19) World Intellectual Property Organization International Bureau



556145

(43) International Publication Date 18 November 2004 (18.11.2004)

(10) International Publication Number WO 2004/099410 A2

(51) International Patent Classification7:

C12N 15/11

(74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(21) International Application Number:

PCT/CA2004/000697

(22) International Filing Date:

7 May 2004 (07.05.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/469,000

9 May 2003 (09.05.2003)

- (71) Applicant (for all designated States except US): TRANS-

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
 - KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every

(71) Applicant (for all designated States except US): TRANSFERT PLUS [CA/CA]: 550 Sherbrooke West, Suite 100, Montréal, Québec_H3A 1B9 (CA).

(72) Inventors; and (75) Inventors/Applicants (for US only): BELIVEAU, Richard [CA/CA]: 266, Wilson, Montréal, Québec H3E 1L8 (CA). DEMEULE, Mitchel [CA/CA]: 3557, Archambult, Longeucii, Québec BWA V82 (CA). BERTRAND, Vanick [CA/CA]: Apartment 6, 860, Marmier, Longeucii, Québec H4 482 (CA). MICHAUD-LEVESQUE, Jonathan [CA/CA]: 7718, Berri, Montréal, Québec H2R 299 (CA). ROILAND, Vanneke [CA/CA]: 554, Chabot, Montréal, Québec H2G 275 (CA). JODOIN, Julie [CA/CA]: 1965, Fullum, Montréal, Québec H2K 3N3 (CA).

(54) Title: COMPOUND AND METHOD FOR REGULATING PLASMINOGEN ACTIVATION AND CELL MIGRATION 109/sis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel paramaceutical compositions form regulating cell migration, plasminogen activator (IPA) and plasminogen with melanotransferrin (p97) for a time a solution of pro-urokinase (uPA) or tissue plasminogen activator (IPA) and plasminogen with melanotransferrin (p97) for a time cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.

